Treatment efficacy of high‐dose creatine supplementation in a child with creatine transporter (SLC6A8) deficiency

• Main Authors: Kaili Shi, Huimin Zhao, Shuming Xu, Hong Han, Wenjuan Li
• Format: Article
• Language: English
• Published: Wiley 2021-04-01
• Series: Molecular Genetics & Genomic Medicine
• Subjects: cerebral creatine deficiency; creatine; H‐MRS; SLC6A8
• Online Access: https://doi.org/10.1002/mgg3.1640

Abstract Background Creatine transporter deficiency is an inborn error of metabolism caused by a deficiency in the creatine transporter protein encoded by the SLC6A8 gene. Previous treatment with creatine supplementation, either alone or in combination with creatine precursors (arginine or glycine), has been attempted; the efficacy of therapy, however, remains controversial. Methods and Results To analyze the treatment efficacy of high‐dose creatine supplementation on creatine transporter deficiency, we reported a child diagnosed with creatine transporter deficiency, who was treated with a conventional dose of creatine (400 mg/kg/d) for 1 month, then twice the dose (800 mg/kg/d) for 2 months, and finally 3 times the dose (1200 mg/kg/d) for 3 months. The patient tolerated the treatment well and showed improvements in muscle mass and strength when the creatine dose was gradually increased to 1200 mg/kg/d. However, when assessed by proton magnetic resonance spectroscopy (H‐MRS), the brain creatine concentration did not increase, and there was no improvement in speech and neurodevelopmental symptoms. Conclusion We conclude that high‐dose creatine supplementation (1200 mg/kg/d) alone improved muscular symptoms, but did not improve cognitive symptoms and brain creatine concentration assessed using H‐MRS. Therefore, new treatment strategies are required for the management of creatine transporter deficiency.